Reviewed By
Reviewed By
Overview
SCIENTIFIC SCORE
Questionable
Based on 16 Researches
6.8
USERS' SCORE
Good
Based on 15 Reviews
8.3
Supplement Facts
Serving Size: 2 Veg Capsules
Amount Per Serving
%DV
Acetyl-L-Carnitine (from Acetyl-L-Carnitine HCl)
1 g (1,000 mg)
**
Top Medical Research Studies
9
We investigated how acetyl-L-carnitine (ALC) might help patients suffering from chemotherapy-induced peripheral neuropathy (CIPN). In a well-structured study involving 239 patients, we divided participants into two groups—one receiving ALC and the other a placebo.
After eight weeks, a significant number of ALC patients showed improvement in their neuropathy symptoms compared to those receiving the placebo.
Additionally, ALC treatment not only reduced neuropathy but also eased cancer-related fatigue without notable safety concerns. Our findings suggest ALC can be an effective option in treating CIPN.
After eight weeks, a significant number of ALC patients showed improvement in their neuropathy symptoms compared to those receiving the placebo.
Additionally, ALC treatment not only reduced neuropathy but also eased cancer-related fatigue without notable safety concerns. Our findings suggest ALC can be an effective option in treating CIPN.
Read More
8
We examined the effects of Acetyl-L-Carnitine (ALCAR) on nerve regeneration in animal studies, particularly focusing on peripheral neuropathies caused by injuries.
This systematic review and meta-analysis considered various studies that administered ALCAR to rats with sciatic nerve injuries.
While ALCAR showed promise in improving pain tolerance and reducing damage, the specific mechanisms behind its benefits remain unclear and warrant further investigation.
This systematic review and meta-analysis considered various studies that administered ALCAR to rats with sciatic nerve injuries.
While ALCAR showed promise in improving pain tolerance and reducing damage, the specific mechanisms behind its benefits remain unclear and warrant further investigation.
Read More
8
We examined the effectiveness of acetyl-L-carnitine (ALC) in treating painful peripheral neuropathy. Our analysis included 14 trials featuring patients suffering from this condition, notably those with diabetes or HIV-related neuropathy.
A meta-analysis demonstrated that ALC led to a significant 20.2% reduction in pain compared to a placebo. Additionally, ALC showed promising results regarding nerve function improvement and regeneration, along with a favorable safety profile.
Although findings are encouraging, further research is needed to fine-tune dosage and treatment duration.
A meta-analysis demonstrated that ALC led to a significant 20.2% reduction in pain compared to a placebo. Additionally, ALC showed promising results regarding nerve function improvement and regeneration, along with a favorable safety profile.
Although findings are encouraging, further research is needed to fine-tune dosage and treatment duration.
Read More
Most Useful Reviews
9
Improved sensation
16 people found this helpful
Great product! My acupuncturist suggested 1500 mg per day for neuropathy in my feet and legs. On the first day, I immediately felt sensation in my feet that I hadn’t experienced for a long time. I also have more energy and can walk further now. I will continue using this form of ALC alongside Alpha Lipoic Acid and other supplements.
Read More
9
Stopped neuropathy
14 people found this helpful
This product, taken with Alpha Lipoic Acid, stopped the neuropathy in my feet due to a pinched sciatic nerve.
Read More
7.5
Major support
1 people found this helpful
Excellent! Five years ago, Acetyl-L-Carnitine was recommended for my Crohn's disease and it has tremendously helped in managing bowel symptoms. After initially trying it for 30 days, I noticed a difference when I ran out within four days. Now, I keep an extra bottle on hand. It also helps alleviate the neuropathy pain in my left foot.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 16 Researches
6.8
- All Researches
9
ALCAR enhances nerve regeneration
We explored how acetyl-l-carnitine (ALCAR) treatment could boost nerve regeneration when combined with decellularized nerve allografts and adipose-derived stromal cells (ASCs). In our study with seventy rats, we used various groups to assess outcomes after bridging a 10-mm sciatic nerve defect.
ALCAR notably supported the survival of ASCs and increased neurotrophic factor expression in the grafts. Overall, results showed that ALCAR enhanced the regenerative effects of ASCs and acellular grafts, achieving results comparable to traditional nerve autografts.
ALCAR notably supported the survival of ASCs and increased neurotrophic factor expression in the grafts. Overall, results showed that ALCAR enhanced the regenerative effects of ASCs and acellular grafts, achieving results comparable to traditional nerve autografts.
Read More
9
We investigated how acetyl L-carnitine (LAC) influences neuroprotection, pain relief, and hand function in patients suffering from carpal tunnel syndrome (CTS). In this blind study featuring 82 patients over four months, we noted significant improvements in nerve conduction and sensory abilities after LAC treatment.
Pain levels also decreased markedly, especially in pressure-related discomfort. These findings suggest that LAC could be a beneficial therapeutic option for managing symptoms in mild to moderate CTS cases, thanks to its neuroprotective and anti-nociceptive effects.
Pain levels also decreased markedly, especially in pressure-related discomfort. These findings suggest that LAC could be a beneficial therapeutic option for managing symptoms in mild to moderate CTS cases, thanks to its neuroprotective and anti-nociceptive effects.
Read More
9
We investigated how acetyl-L-carnitine (ALC) might help patients suffering from chemotherapy-induced peripheral neuropathy (CIPN). In a well-structured study involving 239 patients, we divided participants into two groups—one receiving ALC and the other a placebo.
After eight weeks, a significant number of ALC patients showed improvement in their neuropathy symptoms compared to those receiving the placebo.
Additionally, ALC treatment not only reduced neuropathy but also eased cancer-related fatigue without notable safety concerns. Our findings suggest ALC can be an effective option in treating CIPN.
After eight weeks, a significant number of ALC patients showed improvement in their neuropathy symptoms compared to those receiving the placebo.
Additionally, ALC treatment not only reduced neuropathy but also eased cancer-related fatigue without notable safety concerns. Our findings suggest ALC can be an effective option in treating CIPN.
Read More
8
We examined the effectiveness of various drug treatments for cardiovascular autonomic neuropathy (CAN) in diabetic patients. Our study included a comprehensive review of randomized controlled trials, focusing on treatments that impact heart rate and blood pressure.
We found that several options, including angiotensin-converting enzyme inhibitors and acetyl L-carnitine, showed significant improvements in autonomic function. However, vitamin B12 alone did not demonstrate efficacy. Our findings suggest that while some treatments are beneficial, others like vitamin B12 monotherapy may not be recommended.
We found that several options, including angiotensin-converting enzyme inhibitors and acetyl L-carnitine, showed significant improvements in autonomic function. However, vitamin B12 alone did not demonstrate efficacy. Our findings suggest that while some treatments are beneficial, others like vitamin B12 monotherapy may not be recommended.
Read More
8
We examined the effects of Acetyl-L-Carnitine (ALCAR) on nerve regeneration in animal studies, particularly focusing on peripheral neuropathies caused by injuries.
This systematic review and meta-analysis considered various studies that administered ALCAR to rats with sciatic nerve injuries.
While ALCAR showed promise in improving pain tolerance and reducing damage, the specific mechanisms behind its benefits remain unclear and warrant further investigation.
This systematic review and meta-analysis considered various studies that administered ALCAR to rats with sciatic nerve injuries.
While ALCAR showed promise in improving pain tolerance and reducing damage, the specific mechanisms behind its benefits remain unclear and warrant further investigation.
Read More
User Reviews
USERS' SCORE
Good
Based on 15 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
9
Improved sensation
16 people found this helpful
Great product! My acupuncturist suggested 1500 mg per day for neuropathy in my feet and legs. On the first day, I immediately felt sensation in my feet that I hadn’t experienced for a long time. I also have more energy and can walk further now. I will continue using this form of ALC alongside Alpha Lipoic Acid and other supplements.
Read More
9
Stopped neuropathy
14 people found this helpful
This product, taken with Alpha Lipoic Acid, stopped the neuropathy in my feet due to a pinched sciatic nerve.
Read More
7.5
Major support
1 people found this helpful
Excellent! Five years ago, Acetyl-L-Carnitine was recommended for my Crohn's disease and it has tremendously helped in managing bowel symptoms. After initially trying it for 30 days, I noticed a difference when I ran out within four days. Now, I keep an extra bottle on hand. It also helps alleviate the neuropathy pain in my left foot.
Read More
10
Eliminated pain
This, combined with Alpha-Lipoic Acid 600, has completely eliminated the pain I had in my feet due to peripheral neuropathy!
Read More
9
Miracle combo
I purchased this product to combine with alpha lipoic acid. The results have been miraculous in reducing the neuropathy in my feet. Before the combination, nights were challenging due to tingling and burning sensations, often keeping me awake.
Read More
Frequently Asked Questions
9
Improved sensation
16 people found this helpful
Great product! My acupuncturist suggested 1500 mg per day for neuropathy in my feet and legs. On the first day, I immediately felt sensation in my feet that I hadn’t experienced for a long time. I also have more energy and can walk further now. I will continue using this form of ALC alongside Alpha Lipoic Acid and other supplements.
7.5
Great help
Great product! L-carnitine, along with Alpha Lipoic Acid 600, is a tremendous aid for my neuropathy. After 6 to 8 weeks, I could already feel the difference.
9
Miracle combo
I purchased this product to combine with alpha lipoic acid. The results have been miraculous in reducing the neuropathy in my feet. Before the combination, nights were challenging due to tingling and burning sensations, often keeping me awake.
10
Eliminated pain
This, combined with Alpha-Lipoic Acid 600, has completely eliminated the pain I had in my feet due to peripheral neuropathy!
7.5
Major support
1 people found this helpful
Excellent! Five years ago, Acetyl-L-Carnitine was recommended for my Crohn's disease and it has tremendously helped in managing bowel symptoms. After initially trying it for 30 days, I noticed a difference when I ran out within four days. Now, I keep an extra bottle on hand. It also helps alleviate the neuropathy pain in my left foot.
6
Reduced neuropathy symptoms
Helping with peripheral neuropathy... I began taking Acetyl-L-Carnitine, ALA, Benfotiamine, D3 & K2, B12 and B6 six weeks ago, and I've noticed a reduction in the mild neuropathy in my toes. I've combined this with nerve stretching and high-intensity interval training, making it difficult to determine which part of the regimen is effective. As always with vitamins, your results may differ!
7.5
Effective neuropathy support
I previously used Acetyl-L-Carnitine with alpha-lipoic acid for neuropathy, which was excellent support. NOW, the A-L-Carnitine capsules are of good size and quality.
8
We examined the effectiveness of acetyl-L-carnitine (ALC) in treating painful peripheral neuropathy. Our analysis included 14 trials featuring patients suffering from this condition, notably those with diabetes or HIV-related neuropathy.
A meta-analysis demonstrated that ALC led to a significant 20.2% reduction in pain compared to a placebo. Additionally, ALC showed promising results regarding nerve function improvement and regeneration, along with a favorable safety profile.
Although findings are encouraging, further research is needed to fine-tune dosage and treatment duration.
A meta-analysis demonstrated that ALC led to a significant 20.2% reduction in pain compared to a placebo. Additionally, ALC showed promising results regarding nerve function improvement and regeneration, along with a favorable safety profile.
Although findings are encouraging, further research is needed to fine-tune dosage and treatment duration.
9
We investigated how acetyl-L-carnitine (ALC) might help patients suffering from chemotherapy-induced peripheral neuropathy (CIPN). In a well-structured study involving 239 patients, we divided participants into two groups—one receiving ALC and the other a placebo.
After eight weeks, a significant number of ALC patients showed improvement in their neuropathy symptoms compared to those receiving the placebo.
Additionally, ALC treatment not only reduced neuropathy but also eased cancer-related fatigue without notable safety concerns. Our findings suggest ALC can be an effective option in treating CIPN.
After eight weeks, a significant number of ALC patients showed improvement in their neuropathy symptoms compared to those receiving the placebo.
Additionally, ALC treatment not only reduced neuropathy but also eased cancer-related fatigue without notable safety concerns. Our findings suggest ALC can be an effective option in treating CIPN.
4
We analyzed the effectiveness of dietary interventions and supplements in managing chronic neuropathic pain. Following strict research guidelines, we reviewed 40 studies focusing on conditions like chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy.
While some treatments showed potential, acetyl L-carnitine appeared ineffective or possibly harmful. We couldn't recommend its use for pain management. However, alpha-lipoic acid and vitamin D were found to be beneficial for diabetic neuropathy. More research is needed to clarify these results.
While some treatments showed potential, acetyl L-carnitine appeared ineffective or possibly harmful. We couldn't recommend its use for pain management. However, alpha-lipoic acid and vitamin D were found to be beneficial for diabetic neuropathy. More research is needed to clarify these results.
7
We conducted a robust study comparing acetyl-L-carnitine (ALC) and methylcobalamin (MC) for treating diabetic peripheral neuropathy.
Over 24 weeks, we enrolled over 230 diabetic patients, with half receiving ALC and the other half MC.
Both treatments significantly reduced symptoms of neuropathy without notable side effects, yet neither showed superiority over the other.
This suggests that ALC is as effective as MC for managing neuropathy symptoms and improving nerve function.
Over 24 weeks, we enrolled over 230 diabetic patients, with half receiving ALC and the other half MC.
Both treatments significantly reduced symptoms of neuropathy without notable side effects, yet neither showed superiority over the other.
This suggests that ALC is as effective as MC for managing neuropathy symptoms and improving nerve function.
References
- Aldendail CF, Chen P, Dibble HS, Baute Penry V. A Comprehensive Review of Safety, Efficacy, and Indications for the Use of Alpha-Lipoic Acid and Acetyl-L-Carnitine in Neuropathic Pain. Integr Med (Encinitas). 2024;23:32.
- Frediani JK, Lal AA, Kim E, Leslie SL, Boorman DW, et al. The role of diet and non-pharmacologic supplements in the treatment of chronic neuropathic pain: A systematic review. Pain Pract. 2024;24:186. 10.1111/papr.13291
- Goh JK, Koh L. Evaluating treatment options for cardiovascular autonomic neuropathy in patients with diabetes mellitus: a systematic review. Diabetol Int. 2023;14:224. 10.1007/s13340-023-00629-x
- Pourshahidi S, Shamshiri AR, Derakhshan S, Mohammadi S, Ghorbani M. The Effect of Acetyl-L-Carnitine (ALCAR) on Peripheral Nerve Regeneration in Animal Models: A Systematic Review. Neurochem Res. 2023;48:2335. 10.1007/s11064-023-03911-1
- Kencebay Manas C, Derin N, Arican RY, Tanriover G, Dilmac S, et al. Comparison of the therapeutic effects of erythropoietin and acetyl-l-carnitine on sciatic nerve injury in rats. Neurol Res. 2022;44:659. 10.1080/01616412.2022.2029293
- Parisi S, Ditto MC, Borrelli R, Fusaro E. Efficacy of a fixed combination of palmitoylethanolamide and acetyl-l-carnitine (PEA+ALC FC) in the treatment of neuropathies secondary to rheumatic diseases. Minerva Med. 2021;112:492. 10.23736/S0026-4806.21.07486-3
- Baute V, Zelnik D, Curtis J, Sadeghifar F. Complementary and Alternative Medicine for Painful Peripheral Neuropathy. Curr Treat Options Neurol. 2019;21:44. 10.1007/s11940-019-0584-z
- Di Stefano G, Di Lionardo A, Galosi E, Truini A, Cruccu G. Acetyl-L-carnitine in painful peripheral neuropathy: a systematic review. J Pain Res. 2019;12:1341. 10.2147/JPR.S190231
- Mohammad-Bagher G, Arash A, Morteza BR, Naser MS, Ali M. Synergistic Effects of Acetyl-l-Carnitine and Adipose-Derived Stromal Cells on Improving Regenerative Capacity of Acellular Nerve Allograft in Sciatic Nerve Defect. J Pharmacol Exp Ther. 2019;368:490. 10.1124/jpet.118.254540
- Dinicola S, Fuso A, Cucina A, Santiago-Reyes M, Verna R, et al. Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy. Eur Rev Med Pharmacol Sci. 2018;22:4739. 10.26355/eurrev_201807_15534
- Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, et al. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst. 2018;110:669. 10.1093/jnci/djx259
- Cruccu G, Di Stefano G, Fattapposta F, Jann S, Padua L, et al. L-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain. CNS Drugs. 2017;31:1103. 10.1007/s40263-017-0476-2
- Mostacci B, Liguori R, Cicero AF. Nutraceutical Approach to Peripheral Neuropathies: Evidence from Clinical Trials. Curr Drug Metab. 2018;19:460. 10.2174/1389200218666171031145419
- Sun Y, Shu Y, Liu B, Liu P, Wu C, et al. A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy. Exp Ther Med. 2016;12:4017. 10.3892/etm.2016.3871
- Li S, Chen X, Li Q, Du J, Liu Z, et al. Effects of acetyl-L-carnitine and methylcobalamin for diabetic peripheral neuropathy: A multicenter, randomized, double-blind, controlled trial. J Diabetes Investig. 2016;7:777. 10.1111/jdi.12493
- Callander N, Markovina S, Eickhoff J, Hutson P, Campbell T, et al. Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. Cancer Chemother Pharmacol. 2014;74:875. 10.1007/s00280-014-2550-5
